In traditional pharmacology, the greatest challenge is not just finding a molecule that kills a disease, but ensuring that molecule reaches the disease without harming the rest of the body. Most small-molecule drugs distribute evenly throughout the bloodstream, leading to systemic toxicity. However, a diverse body of research has converged on a physical solution to this biological problem: the Enhanced Permeability and Retention (EPR) effect.
By engineering therapeutic agents into nanoparticles of specific sizes, researchers can exploit the structural flaws of diseased tissue to achieve "passive targeting"—concentrating drugs where they are needed simply by letting them leak into the right places and stay there.
The Geometry of Leaky Vasculature
The EPR effect relies on a fundamental physiological difference between healthy and pathological tissues. In healthy tissue, blood vessels are tightly constructed to prevent large molecules from escaping. However, in rapidly growing tumors or inflamed areas, the process of building new blood vessels (angiogenesis) is rushed and chaotic.
As noted by Zhiping Yuan and colleagues in their work on liposomal Quercetin, these "leaky" vessels feature large fenestrations—gaps in the vessel wall. While healthy vessels keep nanoparticles contained, these gaps allow particles to spill out into the interstitial space of the diseased tissue.
Crucially, this is a one-way street. Diseased tissues often suffer from impaired lymphatic drainage. Once a nanoparticle leaks out of a vessel and into a tumor, there is no functional "drainage system" to remove it. This leads to the retention part of the EPR effect, where therapeutic agents accumulate at concentrations far higher than those found in healthy organs.
Finding the Size-Dependent "Goldilocks" Zone
The success of passive targeting is almost entirely dependent on the physical dimensions of the nanocarrier. Researchers have identified specific size ranges that balance the need to penetrate leaky vessels with the need to avoid the body's natural clearance mechanisms.
- Avoiding the Kidneys and Spleen: Jie Meng and Wei Liang demonstrated that nanocarriers engineered to approximately 50nm are small enough to exploit the EPR effect but large enough to avoid renal filtration (which clears very small molecules) and splenic uptake (which traps larger ones).
- Deep Tissue Penetration: For dense tumor masses, even smaller particles are required. Wanwan Lv showed that particles with a hydrodynamic diameter of ~13nm can achieve deeper penetration into ovarian carcinoma tissues than larger counterparts.
- Crossing the Blood-Brain Barrier: In the context of brain tumors, Jin-Hua Gao and Zhonglan Wang found that liposomes sized between 150-160nm could leverage cellular processes like pinocytosis to cross the blood-brain barrier, a feat impossible for most free-form drugs.
Beyond Cancer: Inflammation and Atherosclerosis
While the EPR effect is most famously associated with oncology, recent work shows it is a universal mechanism for targeting many forms of "vulnerable" or damaged tissue.
In the treatment of myocardial infarction, Aixia Xu and Xiaogang Li utilized PLGA nanoparticles to passively accumulate in damaged heart tissue, where vascular permeability is naturally increased. Similarly, Renfeng Liu and Huawei He showed that silk-engineered nanoparticles naturally concentrate at sites of acute lung and kidney injury by exploiting the increased phagocytic activity and permeability of inflamed zones.
Even in chronic conditions like atherosclerosis, the EPR effect plays a role. Menglin Wu and Xuening Zhang have highlighted how nanomedicines can identify "vulnerable" plaques by accumulating in the dysfunctional vasculature that surrounds unstable arterial lesions.
The Dominance of Passive Over Active Targeting
A surprising insight from this field is that the physical "leakiness" of the environment often matters more than the chemical "keys" we put on the nanoparticles. While many researchers add active targeting ligands (like antibodies or peptides) to the surface of nanoparticles to seek out specific receptors, the EPR effect remains the primary driver of accumulation.
Yuling Xiao and Hao Hong observed that even with active ligands, the structural leakiness of tumor vasculature dictates the final concentration of nanocarriers. This suggests that while active targeting might help with cell uptake once the particle arrives, the EPR effect is the "heavy lifter" that handles the actual delivery to the site.
Reaching the Nucleus
The ultimate frontier of this size-based targeting is the cell nucleus. Yanli Wang and Haifang Wang demonstrated that by shrinking nanostructures (like titania nanotubes) to below 10 nanometers, they could facilitate passage through the nuclear pore complex. This represents the final stage of passive targeting: moving from the bloodstream, through the leaky vessel wall, and finally through the selective gateway of the nuclear membrane to deliver DNA-targeting therapies directly to the genetic heart of the cell.